Your participation is important (in-person or by webinar), so please do not miss this very important meeting)! It will demonstrate critical need if many people attend!!
Date: June 10, 2014
Time: 9:00 am to 1:00 pm EST
Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31, Room 1503A (Great Room), Silver Spring, MD 20993
On June 10, 2014, FDA will be conducting a public meeting on Neurologic Manifestations of Inborn Errors of Metabolism (IEM) Patient-Focused Drug Development. For this meeting, FDA is interested in obtaining patient input on the neurologic/neuropsychological signs, symptoms, and daily impacts that matter most to patients, and current available approaches to treat the neurologic manifestations of inborn errors of metabolism. For each of these topics, a panel of patients and patient representatives/advocates will present comments to begin the dialogue and will be followed by a facilitated discussion inviting comments from all patients and patient representatives in the audience.
Patients or their parents/caregivers may be included on the panel and will be asked to indicate whether they wish to be considered in their registration and by submitting a brief summary of responses to the topic questions during their registration. REGISTRATION FOR THE FDA PUBLIC MEETING CLOSES ON MAY 30, 2014.
You can register to attend in person or by webinar but you must register by May 30, 2014
To learn more about the FDA Public Meeting on Inborn Errors of Metabolism Patient-Focused Drug Development, and to register to attend either in-person or via webcast, visit the FDA website.
If you want more information on attending, contact Stephanie Bozarth at email@example.com.